TransMedics Group Inc (TMDX) - Net Assets
Based on the latest financial reports, TransMedics Group Inc (TMDX) has net assets worth $473.10 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.07 Billion) and total liabilities ($595.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TMDX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $473.10 Million |
| % of Total Assets | 44.28% |
| Annual Growth Rate | 23.33% |
| 5-Year Change | 597.23% |
| 10-Year Change | 1119.68% |
| Growth Volatility | 238.45 |
TransMedics Group Inc - Net Assets Trend (2006–2025)
This chart illustrates how TransMedics Group Inc's net assets have evolved over time, based on quarterly financial data. Also explore TMDX total assets for the complete picture of this company's asset base.
Annual Net Assets for TransMedics Group Inc (2006–2025)
The table below shows the annual net assets of TransMedics Group Inc from 2006 to 2025. For live valuation and market cap data, see TMDX company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $473.10 Million | +106.95% |
| 2024-12-31 | $228.60 Million | +66.62% |
| 2023-12-31 | $137.20 Million | -26.78% |
| 2022-12-31 | $187.38 Million | +176.14% |
| 2021-12-31 | $67.85 Million | -34.69% |
| 2020-12-31 | $103.89 Million | +90.11% |
| 2019-12-31 | $54.65 Million | +1232.62% |
| 2018-12-31 | $-4.83 Million | +97.14% |
| 2017-12-31 | $-168.72 Million | -534.98% |
| 2016-12-31 | $38.79 Million | +340.53% |
| 2006-12-31 | $8.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TransMedics Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21231500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $750.93 Million | 158.72% |
| Other Comprehensive Income | $124.00K | 0.03% |
| Total Equity | $473.10 Million | 100.00% |
TransMedics Group Inc Competitors by Market Cap
The table below lists competitors of TransMedics Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Viohalco S.A
BR:VIO
|
$3.43 Billion |
|
SIASUN Robot Automation Co
SHE:300024
|
$3.43 Billion |
|
Nuscale Power Corp
NYSE:SMR
|
$3.43 Billion |
|
COSCO SHIPPING Specialized Carriers Co Ltd
SHG:600428
|
$3.44 Billion |
|
Essence Fastening Systems (Shanghai) Co. Ltd.
SHE:301005
|
$3.43 Billion |
|
China Airlines Ltd
TW:2610
|
$3.43 Billion |
|
Willscot Mobile Mini Holdings Corp A
NASDAQ:WSC
|
$3.43 Billion |
|
Centerra Gold Inc
TO:CG
|
$3.43 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TransMedics Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 228,603,000 to 473,100,000, a change of 244,497,000 (107.0%).
- Net income of 190,291,000 contributed positively to equity growth.
- Share repurchases of 138,000 reduced equity.
- Other comprehensive income increased equity by 488,000.
- Other factors increased equity by 53,856,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $190.29 Million | +40.22% |
| Share Repurchases | $138.00K | -0.03% |
| Other Comprehensive Income | $488.00K | +0.1% |
| Other Changes | $53.86 Million | +11.38% |
| Total Change | $- | 106.95% |
Book Value vs Market Value Analysis
This analysis compares TransMedics Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.57x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 37.33x to 8.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $2.68 | $100.01 | x |
| 2017-12-31 | $-11.65 | $100.01 | x |
| 2018-12-31 | $-0.25 | $100.01 | x |
| 2019-12-31 | $3.85 | $100.01 | x |
| 2020-12-31 | $4.21 | $100.01 | x |
| 2021-12-31 | $2.46 | $100.01 | x |
| 2022-12-31 | $6.34 | $100.01 | x |
| 2023-12-31 | $4.22 | $100.01 | x |
| 2024-12-31 | $6.49 | $100.01 | x |
| 2025-12-31 | $11.67 | $100.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TransMedics Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 40.22%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 31.43%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 2.26x
- Recent ROE (40.22%) is above the historical average (-18.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.99 Million |
| 2016 | -62.04% | -387.58% | 0.11x | 1.50x | $-27.94 Million |
| 2017 | 0.00% | -270.96% | 0.21x | 0.00x | $-3.95 Million |
| 2018 | 0.00% | -182.50% | 0.31x | 0.00x | $-23.27 Million |
| 2019 | -61.39% | -142.12% | 0.22x | 1.93x | $-39.01 Million |
| 2020 | -27.67% | -112.13% | 0.17x | 1.46x | $-39.14 Million |
| 2021 | -65.16% | -146.11% | 0.22x | 1.99x | $-51.00 Million |
| 2022 | -19.34% | -38.77% | 0.34x | 1.48x | $-54.97 Million |
| 2023 | -18.24% | -10.36% | 0.34x | 5.15x | $-38.75 Million |
| 2024 | 15.51% | 8.03% | 0.55x | 3.52x | $12.60 Million |
| 2025 | 40.22% | 31.43% | 0.57x | 2.26x | $142.98 Million |
Industry Comparison
This section compares TransMedics Group Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TransMedics Group Inc (TMDX) | $473.10 Million | 0.00% | 1.26x | $3.43 Billion |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic con… Read more